Cardiovascular
Cardiovascular
Womens Health
Women's Health
two kidneys
Nephrology
Oncology
Oncology
Ophthalmology
Ophthalmology
Respiratory
Respiratory
Bayer for ProfessionalsYour Resource Portal

ESMO 2024 Shorts Series

Insights from leading oncologists on topics in prostate cancer treatment

ESMO 2024 Banner

Welcome to our dedicated ESMO 2024 Shorts Series, where we present exclusive insights from leading oncologists on topics in prostate cancer treatment, filmed at the European Society of Medical Oncology Annual Congress in Barcelona 2024.

 

Featuring:

  • Part ONE | ESMO talks 2024: Let's discuss a complex mHSPC patient case study
    • With Dr. Mark Prentice (Consultant Clinical Oncologist, Royal Free Hospital NHS Foundation Trust)
  • Part TWO | ESMO talks 2024: The RECORD study + anticoagulants DDI subanalysis
    • With Prof. Amit Bahl (Consultant Clinical Oncologist, University Hospitals Bristol and Chair of the British Uro-Oncology Group)

ESMO talks 2024: Let's discuss a complex mHSPC patient case study - with Dr. Mark Prentice

Delve into a complex metastatic hormone-sensitive prostate cancer (mHSPC) case study with Dr Mark Prentice. hear insights about his treatment approaches, and key considerations in selecting the appropriate patient for treatment.

NUBEQA Prescribing Information

Speakers
    • Dr Mark
      Dr Mark Prentice

    Dr Mark Prentice is a Consultant Clinical Oncologist, at the Royal Free Hospital in London. Dr Prentice is interested in novel radiotherapy techniques, radio-ligand therapy, the hormonal manipulation of prostate cancer and the management of older people with cancer. He is the principal investigator for multiple clinical trials and has written international guidelines on prostate cancer management.

    • Amit Bahl
      Professor Amit Bahl

    Professor Amit Bahl is Consultant Clinical Oncologist at Bristol Cancer Institute, University Hospitals Bristol, Bristol, UK. He has also been an expert adviser to the National Institute for Health and Care Excellence (NICE) for technology appraisals on new drugs, is actively involved in research and is the Clinical Co-lead for National Kidney Cancer Audit and Chairperson of British Uro-oncology Group.

Stay updated & develop your learning profile

Join the BayerPro HCP learning community

Register Here

Abbreviation: DDI; drug-drug-intereactions

 

PP-NUB-GB-2082 | January 2025